Skip to main content
Top
Published in: Clinical Rheumatology 11/2008

01-11-2008 | Original Article

The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital

Authors: C. L. Teh, J. S. Wong

Published in: Clinical Rheumatology | Issue 11/2008

Login to get access

Abstract

The aim of our study is to describe the pattern, clinical features, treatment regimes, and disease activity among the patients treated for rheumatoid arthritis (RA) in the Sarawak General Hospital. We performed a cross-sectional study of all patients with a diagnosis of RA who received treatment at the General Medical Clinic and the Rheumatology Clinic in Sarawak General Hospital over a 1-year period from 1st June 2006 to 31st May 2007. Demographic data, clinical features, and disease activity of all 154 patients were collected for statistical analysis. Rheumatoid arthritis afflicts all the major racial groups in Sarawak including the native population. Our patients have a mean disease duration of 5.4 years (SD 5.69) and a mean duration of delay in diagnosis RA and initiation of disease-modifying antirheumatic drug (DMARD) treatment of 42.9 months (SD 60.1). They have a low rate of interstitial lung disease (6.5%) and rheumatoid nodules (4.5%). Rheumatoid factor was positive in 65.5% of our patients. They have a mean Disease Activity Score (DAS) 28 score of 4.28 (SD 1.33). Only 12.5% of our patients are in remission with DAS 28 < 2.6 and 30.9% of our patients are having high disease activity with DAS 28 > 5.1. Despite the high usage of DMARDs in Sarawak (>80%), our patients have severe disease with high disease activity indices. This is most likely due to delay in diagnosis and initiating DMARDs in RA patients in Sarawak.
Literature
1.
go back to reference Toh BH, Sengupta S, Ang AH, White JC, Lau KS (1973) A pattern of rheumatoid arthritis in West Malaysia. Ann Rheum Dis 32:151–156PubMedCrossRef Toh BH, Sengupta S, Ang AH, White JC, Lau KS (1973) A pattern of rheumatoid arthritis in West Malaysia. Ann Rheum Dis 32:151–156PubMedCrossRef
2.
go back to reference Veerapen K, Mangat G, Watt I, Dieppe P (1993) The expression of rheumatoid arthritis in Malaysian and British patients: a comparative study. Br J Rheumatol 32:541–545PubMedCrossRef Veerapen K, Mangat G, Watt I, Dieppe P (1993) The expression of rheumatoid arthritis in Malaysian and British patients: a comparative study. Br J Rheumatol 32:541–545PubMedCrossRef
3.
go back to reference Kong KF, Yeap SS, Chow SK, Phipps ME (2002) HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia. Autoimmunity 35:235–239PubMedCrossRef Kong KF, Yeap SS, Chow SK, Phipps ME (2002) HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia. Autoimmunity 35:235–239PubMedCrossRef
4.
go back to reference Abdel-Nasser AM, Rasker JJ, Valkenburg HA (1997) Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 27:123–140PubMedCrossRef Abdel-Nasser AM, Rasker JJ, Valkenburg HA (1997) Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 27:123–140PubMedCrossRef
5.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
6.
go back to reference Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
7.
go back to reference van Riel PL, van Restel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28–i31PubMedCrossRef van Riel PL, van Restel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28–i31PubMedCrossRef
8.
go back to reference Sokka T, Kautiainen H, Toloza S et al (2007) QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66:1491–1496 Epub 2007 Apr 5PubMedCrossRef Sokka T, Kautiainen H, Toloza S et al (2007) QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66:1491–1496 Epub 2007 Apr 5PubMedCrossRef
9.
go back to reference Sokka T, Pincus T (2002) Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 29:2521–2524PubMed Sokka T, Pincus T (2002) Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 29:2521–2524PubMed
10.
go back to reference Ward MM, Fries JF (1998) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 25:408–416PubMed Ward MM, Fries JF (1998) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 25:408–416PubMed
11.
go back to reference Mikuls TR (2000) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. Arthritis Rheum 43:464–467PubMedCrossRef Mikuls TR (2000) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. Arthritis Rheum 43:464–467PubMedCrossRef
12.
go back to reference Klaukka T, Kaarela K (2003) Methotrexate is the leading DMARD in Finland. Ann Rheum Dis 62:494–496PubMedCrossRef Klaukka T, Kaarela K (2003) Methotrexate is the leading DMARD in Finland. Ann Rheum Dis 62:494–496PubMedCrossRef
13.
go back to reference Tsakonas E, Fitzgerald AA, Fitzcharles MA et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 27:623–629PubMed Tsakonas E, Fitzgerald AA, Fitzcharles MA et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 27:623–629PubMed
14.
go back to reference Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927PubMedCrossRef Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927PubMedCrossRef
15.
go back to reference Möttönen T, Hannonen P, Korpela M et al (2002) FIN-RACo Trial Group. Finnish rheumatoid arthritis combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898PubMedCrossRef Möttönen T, Hannonen P, Korpela M et al (2002) FIN-RACo Trial Group. Finnish rheumatoid arthritis combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898PubMedCrossRef
16.
go back to reference Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 364:263–269PubMedCrossRef Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 364:263–269PubMedCrossRef
17.
go back to reference Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90PubMed Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90PubMed
Metadata
Title
The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital
Authors
C. L. Teh
J. S. Wong
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0945-6

Other articles of this Issue 11/2008

Clinical Rheumatology 11/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.